Английская Википедия:Islatravir

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Chembox

Islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine, EFdA, or MK-8591) is an investigational drug for the treatment of HIV infection.[1] It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI).[2] Merck is developing a subdermal drug-eluting implant to administer islatravir.[3][4]

In 2021, FDA placed a partial clinical hold for several studies under Islatravir.[5] The reason was a decline in CD4 T cells under therapy. Merck announced to restart the study program in 2023 with a decreased dose, however studies of islatravir for pre-exposure prophylaxis (PrEP) will be discontinued.[6]

In 2024, results from a phase II study combining islatravir with lenacapavir indicated that the regimen shows promise as a possible weekly oral regimen.[7]

Biological activity

Islatravir has activity against HIV in animal models,[8] and is being studied clinically for HIV treatment and prophylaxis.[9] Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) that unlike other such inhibitors, inhibits HIV through multiple mechanisms,[8] providing rapid suppression of the virus, when tested in macaques and mice.[10] Nevertheless, there are HIV strains resistant to islatravir and research is ongoing.[11][12]

References

Шаблон:Reflist

Шаблон:HIVpharm